Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Genentech Catching Up In Melanoma With Cotellic Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA clears Cotellic/Zelboraf combination, but the company already is testing the addition of a PD-L1 inhibitor.

Advertisement

Related Content

Melanoma Approvals Break New Ground In Immunotherapy
PD-1 Progress May Shorten The Life Of Other Drugs
Franchise Management Likely To Be Theme Of 2015 Oncology Approvals
The Next Wave For Melanoma

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077978

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel